TransMedics Group (NASDAQ:TMDX) Issues Earnings Results

TransMedics Group (NASDAQ:TMDX) issued its earnings results on Wednesday. The company reported ($0.39) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.47) by $0.08, Fidelity Earnings reports. The business had revenue of $7.21 million during the quarter, compared to analyst estimates of $6.67 million.

TMDX traded down $0.64 during midday trading on Friday, hitting $16.61. 196,200 shares of the company were exchanged, compared to its average volume of 89,326. TransMedics Group has a 1-year low of $16.30 and a 1-year high of $31.54. The business has a 50 day moving average price of $19.67. The company has a current ratio of 7.55, a quick ratio of 6.82 and a debt-to-equity ratio of 0.48.

A number of brokerages have weighed in on TMDX. Zacks Investment Research raised TransMedics Group from a “sell” rating to a “hold” rating in a report on Sunday, November 3rd. Cowen cut their price objective on TransMedics Group from $40.00 to $28.00 and set an “outperform” rating on the stock in a report on Thursday. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. TransMedics Group has a consensus rating of “Buy” and an average target price of $33.00.

TransMedics Group Company Profile

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Featured Story: What member countries make up the G-20?

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with's FREE daily email newsletter.